By Counterforce Health Team in Waylivra (volanesorsen) —

How to Get Waylivra (Volanesorsen) Covered by Blue Cross Blue Shield in New York: Complete Requirements Checklist and Appeals Guide

Answer Box: Getting Waylivra Covered by Blue Cross Blue Shield in New York

Waylivra (volanesorsen) requires medical necessity approval from Blue Cross Blue Shield in New York since it's not FDA-approved in the US. The fastest path: (1) Have your specialist submit a comprehensive medical necessity letter documenting confirmed FCS diagnosis and failed conventional therapies, (2) Include genetic testing results and triglyceride levels ≥1,000 mg/dL, and (3) Be prepared to file an external appeal through New York's Department of Financial Services if initially denied—you have 180 days and strong consumer protections in New York.

Table of Contents

Who Should Use This Checklist

This guide is designed for patients with confirmed familial chylomicronemia syndrome (FCS) and their healthcare providers seeking Waylivra coverage through Blue Cross Blue Shield plans in New York. You'll need this checklist if:

  • You have genetic confirmation of FCS or a North American FCS Score ≥45
  • Your triglyceride levels remain ≥1,000 mg/dL despite conventional treatment
  • You've experienced treatment failures with fibrates, omega-3 supplements, or dietary management
  • Your specialist believes Waylivra is medically necessary to prevent pancreatitis

Expected outcome: With proper documentation, medical necessity approvals are possible, though initial denials are common due to Waylivra's non-FDA-approved status in the US. New York's robust appeal process provides strong patient protections.

Member & Plan Basics

Coverage Verification Steps

✓ Confirm active Blue Cross Blue Shield coverage through your member portal or ID card
✓ Identify your specific Blue plan (there are 33 independent Blue plans—requirements may vary)
✓ Check your deductible status and specialty drug copay structure
✓ Verify you haven't reached annual or lifetime maximums

Note: Blue Cross Blue Shield specialty medications typically require prior authorization regardless of plan type. Contact member services at the number on your insurance card to confirm your plan's specific requirements.

Plan Type Considerations

Commercial Plans: Standard medical necessity review process applies
Medicare Advantage: May have additional CMS requirements
Medicaid Managed Care: Subject to state Medicaid policies plus plan requirements

Clinical Criteria Requirements

Primary Indication Requirements

Requirement Documentation Needed Where to Find It
FCS Diagnosis Genetic testing results OR North American FCS Score ≥45 Genetic counselor report or specialist assessment
Triglyceride Levels Fasting levels ≥1,000 mg/dL (multiple measurements) Lab reports from past 6-12 months
Treatment Failures Documentation of fibrate/omega-3 trials and outcomes Provider notes with specific medications, doses, duration, reasons for discontinuation
Specialist Endorsement Letter from lipid specialist or endocrinologist Medical necessity letter with board certification verification

ICD-10 Coding

Primary diagnosis: E78.3 (Hyperchylomicronemia)
Supporting codes: K85.9 (Acute pancreatitis, unspecified) if applicable

Important: Waylivra is not FDA-approved in the United States and has no assigned HCPCS J-code or NDC for US billing. All requests must go through medical necessity exception processes.

Documentation Packet Essentials

Medical Necessity Letter Components

Your specialist's letter must include:

Patient Information

  • Full name, date of birth, policy number
  • Complete medical history relevant to FCS

Clinical Justification

  • Confirmed FCS diagnosis with supporting evidence
  • Detailed triglyceride history showing persistent elevation ≥1,000 mg/dL
  • Comprehensive list of failed conventional therapies with specific outcomes
  • Risk of pancreatitis and hospitalization without treatment
  • Why Waylivra is uniquely appropriate (ApoC-III suppression mechanism)

Monitoring Plan

  • Proposed laboratory monitoring schedule
  • Safety considerations and specialist oversight commitment

Required Attachments Checklist

✓ All triglyceride lab results from past 12 months
✓ Genetic testing report confirming FCS diagnosis
✓ Documentation of prior therapy trials with detailed outcomes
✓ Specialist consultation notes supporting medical necessity
✓ Pancreatitis hospitalization records (if applicable)
✓ Copy of insurance card and member identification

Submission Process

Step-by-Step Submission

  1. Gather Documentation (Patient/Clinic): Collect all required clinical evidence and lab results
  2. Draft Medical Necessity Letter (Specialist): Include all required components listed above
  3. Submit Through Proper Channel (Clinic): Use your Blue Cross Blue Shield provider portal or designated medical necessity fax line (verify current submission method with your plan)
  4. Obtain Confirmation (Clinic): Record submission confirmation number and date
  5. Follow Up (Patient/Clinic): Check status within 5-7 business days
Critical: Include original physician signature—no stamps or electronic signatures accepted. Incomplete submissions are automatically denied.

After Submission: What to Expect

Timeline Expectations

Initial Review: 30 days for standard review
Expedited Review: 72 hours if medical urgency documented
Status Updates: Available through member/provider portals

What to Record

  • Confirmation number and submission date
  • Case number (if assigned)
  • Review timeline communicated by the plan
  • Any additional information requests

Appeals Process in New York

New York provides exceptionally strong patient protections for insurance appeals, making it one of the most favorable states for challenging specialty drug denials.

Internal Appeal (Required First Step)

Timeline: Must file within 180 days of denial
Plan Response Time: 30 days standard, 72 hours expedited
Required: Comprehensive physician attestation with original signature

External Appeal Through New York DFS

If your internal appeal is denied, you have powerful options through the New York State Department of Financial Services.

Key Advantages in New York:

  • 180 days to file external appeal (extended from 60 days as of March 2025)
  • 72-hour decision timeline for specialty drug appeals
  • 24-hour expedited timeline for urgent non-formulary drug denials
  • Binding decisions on insurance companies
  • $25 fee maximum (waived for financial hardship)

Required Forms:

  • Comprehensive Physician Attestation Form
  • Experimental/Investigational Form (since Waylivra isn't FDA-approved)
From our advocates: "Patients in New York have successfully overturned non-formulary specialty drug denials by emphasizing the lack of FDA-approved alternatives for their specific condition and providing comprehensive documentation of treatment failures. The key is demonstrating that conventional therapies have been inadequate and that the requested medication addresses a unique mechanism of action not available through formulary options."

Additional New York Resources

Healthcare Appeals Ombudsman: 1-800-NYS-APPEAL (free assistance with complex appeals)
Community Health Advocates: 888-614-5400 (free counseling on insurance denials)
External Appeals Database: Searchable database of past decisions with medical literature references

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn
"Not FDA-approved in US" Emphasize lack of approved alternatives for FCS; reference EU approval and safety data
"Experimental/investigational" Provide EMA approval documentation; cite published clinical trials
"Alternative therapies available" Document specific failures of fibrates, omega-3s with reasons for discontinuation
"Insufficient documentation" Submit complete genetic testing, specialist consultation, and treatment history
"Not medically necessary" Emphasize pancreatitis risk, hospitalization history, and unique mechanism of action

Cost Support Options

While insurance coverage is the primary goal, consider these additional resources:

Manufacturer Support: Contact Ionis Pharmaceuticals for potential patient assistance programs (verify availability for US patients)

Clinical Trials: Search ClinicalTrials.gov for ongoing FCS studies that might provide access

State Programs: New York's Department of Health may have rare disease support programs

FAQ

How long does Blue Cross Blue Shield prior authorization take in New York?
Standard medical necessity reviews take up to 30 days. Expedited reviews (if medical urgency is documented) must be completed within 72 hours.

What if Waylivra is non-formulary?
All Waylivra requests will be non-formulary since it's not FDA-approved in the US. This means every request goes through medical necessity exception processes rather than standard prior authorization.

Can I request an expedited appeal?
Yes, if you can demonstrate medical urgency (such as recent pancreatitis or very high triglyceride levels). Both internal and external appeals can be expedited in New York.

Does step therapy apply?
Yes, you must document failures or contraindications to conventional FCS treatments including fibrates, omega-3 fatty acids, and dietary management.

What happens if my appeal is denied?
In New York, you can file an external appeal with the Department of Financial Services. Their decision is binding on your insurance company, and New York has one of the strongest external review processes in the country.

How much will this cost me?
Costs depend on your plan's specialty drug tier and deductible. The external appeal process costs a maximum of $25 (waived for financial hardship).

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters and crafting evidence-backed responses. Their platform helps patients and providers navigate complex prior authorization requirements and build compelling cases for specialty medications like Waylivra.

For additional support with your Waylivra appeal, Counterforce Health's platform can help you identify the specific denial reasons and develop targeted responses using the right clinical evidence and payer-specific requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies and coverage criteria can change. Always verify current requirements with your specific Blue Cross Blue Shield plan and consult with your healthcare provider regarding treatment decisions. For personalized assistance with insurance appeals in New York, contact Community Health Advocates at 888-614-5400.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.